Titre : Ferredoxine-NADP reductase

Ferredoxine-NADP reductase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Platelet Transfusion
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Ferredoxine-NADP reductase : Questions médicales les plus fréquentes", "headline": "Ferredoxine-NADP reductase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Ferredoxine-NADP reductase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-31", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Ferredoxine-NADP reductase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Oxidoreductases acting on sulfur group donors", "url": "https://questionsmedicales.fr/mesh/D050862", "about": { "@type": "MedicalCondition", "name": "Oxidoreductases acting on sulfur group donors", "code": { "@type": "MedicalCode", "code": "D050862", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.667" } } }, "about": { "@type": "MedicalCondition", "name": "Ferredoxine-NADP reductase", "alternateName": "Ferredoxin-NADP Reductase", "code": { "@type": "MedicalCode", "code": "D005287", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yoko Kimata-Ariga", "url": "https://questionsmedicales.fr/author/Yoko%20Kimata-Ariga", "affiliation": { "@type": "Organization", "name": "Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Yamaguchi 753-8515, Japan." } }, { "@type": "Person", "name": "Milagros Medina", "url": "https://questionsmedicales.fr/author/Milagros%20Medina", "affiliation": { "@type": "Organization", "name": "Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009 Zaragoza, Spain; Instituto de Biocomputación y Física de Sistemas Complejos (Joint Units: BIFI-IQFR and GBsC-CSIC), Universidad de Zaragoza, 50018 Zaragoza, Spain. Electronic address: mmedina@unizar.es." } }, { "@type": "Person", "name": "Masayuki Miyata", "url": "https://questionsmedicales.fr/author/Masayuki%20Miyata", "affiliation": { "@type": "Organization", "name": "Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Japan." } }, { "@type": "Person", "name": "Toshiharu Hase", "url": "https://questionsmedicales.fr/author/Toshiharu%20Hase", "affiliation": { "@type": "Organization", "name": "Division of Protein chemistry, Institute for Protein Research, Osaka University, Suita, Japan." } }, { "@type": "Person", "name": "Marta Martínez-Júlvez", "url": "https://questionsmedicales.fr/author/Marta%20Mart%C3%ADnez-J%C3%BAlvez", "affiliation": { "@type": "Organization", "name": "Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009 Zaragoza, Spain; Instituto de Biocomputación y Física de Sistemas Complejos (Joint Units: BIFI-IQFR and GBsC-CSIC), Universidad de Zaragoza, 50018 Zaragoza, Spain. Electronic address: mmartine@unizar.es." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.", "datePublished": "2023-07-15", "url": "https://questionsmedicales.fr/article/37452616", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ejh.14049" } }, { "@type": "ScholarlyArticle", "name": "The appropriateness of platelet transfusions in hematological patients and the potential for improvement.", "datePublished": "2022-12-07", "url": "https://questionsmedicales.fr/article/36493919", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.tracli.2022.11.007" } }, { "@type": "ScholarlyArticle", "name": "Acute hemolytic transfusion reaction following ABO-mismatched platelet transfusion: Two case reports.", "datePublished": "2023-02-15", "url": "https://questionsmedicales.fr/article/36805153", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.transci.2023.103658" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of the Association of Platelet Count, Mean Platelet Volume, and Platelet Transfusion With Intraventricular Hemorrhage and Death Among Preterm Infants.", "datePublished": "2022-10-03", "url": "https://questionsmedicales.fr/article/36260331", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2022.37588" } }, { "@type": "ScholarlyArticle", "name": "Immunologic effects of red blood cell and platelet transfusions in neonates.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36165536", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MOH.0000000000000736" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D010088" }, { "@type": "ListItem", "position": 5, "name": "Oxidoreductases acting on sulfur group donors", "item": "https://questionsmedicales.fr/mesh/D050862" }, { "@type": "ListItem", "position": 6, "name": "Ferredoxine-NADP reductase", "item": "https://questionsmedicales.fr/mesh/D005287" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Ferredoxine-NADP reductase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Ferredoxine-NADP reductase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Ferredoxine-NADP reductase", "description": "Comment diagnostiquer une déficience en ferredoxine-NADP réductase ?\nQuels tests sont utilisés pour évaluer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des biomarqueurs associés à cette enzyme ?\nComment évaluer l'impact de l'alimentation sur l'enzyme ?", "url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Platelet+Transfusion&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Ferredoxine-NADP reductase", "description": "Quels sont les symptômes d'une déficience en ferredoxine-NADP réductase ?\nLa déficience peut-elle affecter la croissance des plantes ?\nY a-t-il des signes cliniques chez les animaux ?\nLes symptômes varient-ils selon les espèces ?\nComment les symptômes évoluent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Platelet+Transfusion&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Ferredoxine-NADP reductase", "description": "Comment prévenir une déficience en ferredoxine-NADP réductase ?\nY a-t-il des pratiques agricoles recommandées ?\nLes tests de sol peuvent-ils aider à la prévention ?\nComment la sélection des semences influence-t-elle la prévention ?\nLes conditions climatiques affectent-elles la prévention ?", "url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Platelet+Transfusion&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Ferredoxine-NADP reductase", "description": "Quels traitements existent pour la déficience en ferredoxine-NADP réductase ?\nLes thérapies géniques sont-elles une option ?\nComment l'alimentation peut-elle aider ?\nY a-t-il des médicaments spécifiques recommandés ?\nLes traitements varient-ils selon les espèces ?", "url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Platelet+Transfusion&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Ferredoxine-NADP reductase", "description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle affecter la reproduction des plantes ?\nY a-t-il des risques de maladies associées ?\nLes complications varient-elles selon les espèces ?\nComment les complications impactent-elles l'écosystème ?", "url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Platelet+Transfusion&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Ferredoxine-NADP reductase", "description": "Quels sont les facteurs de risque pour cette déficience ?\nLes variétés de plantes influencent-elles le risque ?\nLe stress hydrique est-il un facteur de risque ?\nLes maladies des plantes augmentent-elles le risque ?\nComment les pratiques agricoles affectent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Platelet+Transfusion&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en ferredoxine-NADP réductase ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des analyses génétiques peuvent confirmer la déficience." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité de l'enzyme ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques mesurant l'activité de la ferredoxine-NADP réductase sont utilisés." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, des troubles métaboliques ou des anomalies de croissance peuvent apparaître." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à cette enzyme ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux de NADPH et de ferredoxine peuvent servir de biomarqueurs indirects." } }, { "@type": "Question", "name": "Comment évaluer l'impact de l'alimentation sur l'enzyme ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des études nutritionnelles peuvent aider à comprendre l'impact des nutriments sur l'activité enzymatique." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en ferredoxine-NADP réductase ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, troubles de la photosynthèse et anomalies métaboliques." } }, { "@type": "Question", "name": "La déficience peut-elle affecter la croissance des plantes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner un retard de croissance et une photosynthèse inefficace." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques chez les animaux ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme une croissance réduite et des troubles métaboliques peuvent être observés." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les espèces ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon les espèces végétales ou animales affectées." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver avec le temps si la déficience n'est pas traitée." } }, { "@type": "Question", "name": "Comment prévenir une déficience en ferredoxine-NADP réductase ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et riche en nutriments peut aider à prévenir cette déficience." } }, { "@type": "Question", "name": "Y a-t-il des pratiques agricoles recommandées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des engrais appropriés et gérer l'irrigation peut améliorer la santé des plantes." } }, { "@type": "Question", "name": "Les tests de sol peuvent-ils aider à la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests de sol réguliers peuvent identifier des carences nutritionnelles potentielles." } }, { "@type": "Question", "name": "Comment la sélection des semences influence-t-elle la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Choisir des semences résistantes peut réduire le risque de déficiences enzymatiques." } }, { "@type": "Question", "name": "Les conditions climatiques affectent-elles la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conditions climatiques extrêmes peuvent exacerber les déficiences enzymatiques." } }, { "@type": "Question", "name": "Quels traitements existent pour la déficience en ferredoxine-NADP réductase ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement spécifique, mais des suppléments nutritionnels peuvent aider." } }, { "@type": "Question", "name": "Les thérapies géniques sont-elles une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore disponible pour cette déficience." } }, { "@type": "Question", "name": "Comment l'alimentation peut-elle aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut soutenir l'activité enzymatique." } }, { "@type": "Question", "name": "Y a-t-il des médicaments spécifiques recommandés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Aucun médicament spécifique n'est recommandé pour traiter cette déficience enzymatique." } }, { "@type": "Question", "name": "Les traitements varient-ils selon les espèces ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent différer entre les plantes et les animaux selon les besoins." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec cette déficience ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles métaboliques graves et une croissance réduite." } }, { "@type": "Question", "name": "La déficience peut-elle affecter la reproduction des plantes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner une réduction de la fertilité et des rendements." } }, { "@type": "Question", "name": "Y a-t-il des risques de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies métaboliques peuvent survenir en raison de l'accumulation de métabolites." } }, { "@type": "Question", "name": "Les complications varient-elles selon les espèces ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent varier selon les espèces végétales ou animales affectées." } }, { "@type": "Question", "name": "Comment les complications impactent-elles l'écosystème ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des déficiences généralisées peuvent affecter la chaîne alimentaire et la biodiversité." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour cette déficience ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs incluent une mauvaise nutrition, des conditions de sol défavorables et le stress environnemental." } }, { "@type": "Question", "name": "Les variétés de plantes influencent-elles le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines variétés sont plus susceptibles de développer des déficiences enzymatiques." } }, { "@type": "Question", "name": "Le stress hydrique est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress hydrique peut aggraver les déficiences en ferredoxine-NADP réductase." } }, { "@type": "Question", "name": "Les maladies des plantes augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies peuvent compromettre la santé des plantes et augmenter le risque de déficiences." } }, { "@type": "Question", "name": "Comment les pratiques agricoles affectent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des pratiques agricoles inadéquates peuvent augmenter le risque de déficiences enzymatiques." } } ] } ] }

Sources (7126 au total)

Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.

This study aimed to describe the burden of thrombocytopenia, supportive care practices, bleeding complications and predictors of bleeding in MDS patients within a large Australian hospital network, to... A retrospective cohort study of patients aged ≥18 years with MDS, chronic myelomonocytic leukaemia or MDS/myeloproliferative overlap neoplasm admitted from 2016 to 2018 was conducted. Data were obtain... One hundred seventy-nine patients (median age 78 years, 61.5% male) were identified. The median platelet count at first admission was 90 × 10... Thrombocytopenia is common in MDS. Although guidelines recommend otherwise, prophylactic platelet transfusions were commonly used for severe thrombocytopenia. Despite the majority of patients receivin...

The appropriateness of platelet transfusions in hematological patients and the potential for improvement.

Hematology patients are intensive platelet users. In clinical practice, a substantial proportion of platelet (PLT) transfusions are routinely administered outside the guidelines despite compelling evi... The audit of all PLT orders for adult hematological inpatients was conducted over 2 months. The assessment was performed using guidelines for PLT transfusion. Patient demographic, clinical, and transf... Based on 286 PLT orders, 344 PCs were transfused to 67 patients: 235 (82.2%) prophylactical due to low PLT count, 34 (11.9%) preprocedural and 17 (5.9%) therapeutic. Overall, 105 (36.77%) PLT transfus... Our audit of PLT transfusion practice found a large proportion of inappropriate PLT transfusions. Based on the most common deviations from the guidelines a variety of targeted measures for improvement...

Evaluation of the Association of Platelet Count, Mean Platelet Volume, and Platelet Transfusion With Intraventricular Hemorrhage and Death Among Preterm Infants.

Platelet transfusion is commonly performed in infants to correct severe thrombocytopenia or prevent bleeding. Exploring the associations of platelet transfusion, platelet count (PC), and mean platelet... To evaluate the associations of platelet transfusion, PC, and MPV with IVH and in-hospital mortality and to explore whether platelet transfusion-associated IVH and mortality risks vary with PC and MPV... This retrospective cohort study included preterm infants who were transferred to the neonatal intensive care unit on their day of birth and received ventilation during their hospital stay. The study w... Platelet transfusion, PC, and MPV.... Any grade IVH, severe IVH (grade 3 or 4), and in-hospital mortality.... Among the 1221 preterm infants (731 [59.9%] male; median [IQR] gestational age, 31.0 [29.0-33.0] weeks), 94 (7.7%) received 166 platelet transfusions. After adjustment for potential confounders, plate... In preterm infants, platelet transfusion, PC, and MPV were associated with mortality, and PC was also associated with any grade IVH and severe IVH. The findings suggest that a lower platelet transfusi...

Immunologic effects of red blood cell and platelet transfusions in neonates.

Premature neonates are frequently transfused red blood cells (RBCs) or platelets to raise hemoglobin or platelet counts. However, these transfusions may have unintended effects on the immune system. T... Neonatal RBC transfusions are associated with increases in plasma pro-inflammatory cytokines, but recent findings suggest sex-specific differential responses. At least one cytokine (monocyte chemoattr... RBC and platelet transfusions alter neonatal immune and inflammatory responses. Their pro-inflammatory effects might worsen neonatal disease or affect neurodevelopmental outcomes....

Thromboelastography in guiding preventive platelet transfusion in patients with haematologic diseases.

This study analysed the relationships between the main thromboelastography (TEG) parameters, the platelet (PLT) count and clinical bleeding in patients with blood diseases. We explored the threshold o... In total, 268 patients with clear diagnoses of blood diseases and thrombocytopenia were enrolled and divided into five groups, A, B, C, D and E, corresponding to PLT counts of 0-10 × 10... The maximum amplitude (MA) in groups A, B and C increased gradually, with a significant difference between each pair of these groups (P < 0.05). In groups A, B, C, D and E, the corresponding MA at the... The MA can be used as a reference indicator for preventive PLT transfusion to a certain extent. When the PLT count is within different ranges, the MA threshold for preventive PLT transfusion also diff...

Platelet transfusion in critical care: A new method to analyze transfusion practice based on decision time intervals.

While prior studies of platelet transfusion in critical care have focused on transfusions given, proper analysis of clinical transfusion practice also requires consideration of the decision not to tra... We introduce a new method to assess transfusion practice based on decision time intervals (DTIs). Each patient's intensive care (ICU) stay was segmented into a series of DTIs defined by a time interva... Among 6125 ICU patients treated between October 2016 and October 2021, we analyzed 39,745 DTIs among patients (n = 2921) who had at least one DTI with thrombocytopenia (≤150,000/μL). We found no assoc... DTI analysis represents a new method to assess transfusion practice that considers both transfusions given and not given, and that analyzes clinical circumstances present when decisions regarding tran...

A meta-analysis of risk factors associated with platelet transfusion refractoriness.

Platelet transfusion refractoriness (PTR) remains an intractable issue in clinical practice, and is common in hematological patients. At present, it is believed that both immune and non-immune factors... PubMed, Embase, Cochrane library, and Web of Science were selected as research database platforms. Citations included were further assessed for quality and bias using the Newcastle-Ottawa Scale. All a... The preliminary search revealed 1069 publications, and 17 (5929 patients in total) were ultimately included in the quantitative analysis. The following variables were associated with the occurrence of... We identified some important risk factors for PTR, but further research is needed to identify the many other possible elements that may contribute to or mediate PTR....